替莫唑胺有哪几个版本?分别多少钱?

Temozolomide is a drug used to treat certain types of brain tumors, specifically glioblastoma multiforme. There are different versions of temozolomide on the market, including the brand-name drug and several generic versions. This article will introduce these versions and their prices in detail, and discuss the drug’s listing and medical insurance status in China.

What versions of temozolomide are there

Indian Cipla version

Indian Cipla has two specifications of temozolomide, 100mg*5 capsules/box and 250mg*5 capsules/box.

Hydron India version

Hydron India produces temozolomide in three specifications: 100mg*5 capsules/box, 20mg*5 capsules/box, and 250mg*5 capsules/box.

Generic drugs also need to follow international standards for production and quality control to ensure that they can meet the treatment needs of patients.

How much do the different versions of temozolomide cost?

The price of the Cipla version in India

For patients looking for a more economical treatment option, the generic version of temozolomide provided by Cipla in India is a good choice. Among them, the price of 100mg*5 pills/box is about US$21 per box, while the price of 250mg*5 pills/box is about US$39 per box.

This price advantage allows more patients to afford necessary treatments, helping to improve their health.

The price of the Indian version of Hydron

The price of the generic version of temozolomide produced by Hydron in India is slightly different. The price of 100mg*5 pills/box is about US$38 per box, the price of 20mg*5 pills/box is US$34 per box, and the price of 250mg*5 pills is as high as about US$51 per box.

Despite the difference in price, this provides patients with the flexibility to choose the treatment that best suits their circumstances.

Temozolomide’s marketing and medical insurance status in China

Temozolomide’s marketing status in China

Temozolomide has been launched in China, bringing new hope to Chinese patients. As a key drug in the treatment of specific types of brain tumors, its introduction has greatly enriched domestic treatment options.

With the launch of the drug in the Chinese market, more and more medical institutions are beginning to use it to treat eligible patients.

Information on entering the medical insurance system

Temozolomide has not only been launched in China, but has also entered the Chinese medical insurance system. This means that eligible patients can be reimbursed for part of the cost through medical insurance, reducing the financial burden on individuals and families.

There are many generic drugs on the market to choose from, which further increases patients’ medication choices, while also helping to promote market competition and reduce drug prices.